pharmacoepidemiology is the study of use and effect of drugs in large number of population.
pharmacoepidemiology enhances or supplements the information from the preclinical studies.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Toxicological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Toxicological approach. Contact me through comment section if you need any assistance in understating
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Toxicological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Toxicological approach. Contact me through comment section if you need any assistance in understating
Pharmacological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Pharmacological approach. Contact me through comment section if you need any assistance in understating
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Dinesh Gangoda
Contents
Guidelines for Preparation of Documentation
Clinical Study Reports
Clinical Trial Monitoring
Safety Monitoring in clinical trials
Introduction
Proper documentation is critical to the success of a clinical study.
Every aspect of the study must be documented in order to obtain useful data and demonstrate compliance with Good Clinical Practice (GCP) guidelines and with all applicable regulations.
Investigator’s Brochure (IB)
List of Abbreviations
Contents & Summary
Introduction provides the chemical name (and generic and trade names, if approved) of the investigational product.
Physical, chemical and pharmaceutical properties and formulation of the medicinal product. Non-clinical studies & Clinical Studies and their results.
The Investigator's Brochure should be reviewed at least annually and revised as necessary in compliance with a standard procedures established by drug development company.
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
Spontenous adr reporting in india
PASSIVE survillence system, data assement
data aciqsition, data interpretation, what all information required in ADR form, WHEN TO REPORT
BLUE CARD,YELLOW CARD, WHO CODES
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
Epidemiology is the study of occurrence, distribution and determinants of health and
diseases or disorders in man and its application in controlling health problems.
Epidemiology has by tradition two major areas.
First is the study of infectious diseases that spread to large populations, i.e., epidemics.
The second is the study of chronic diseases.
Epidemiological studies help to solve such health problems and provide a basis for
improving living conditions of the people.
During its progress and development, epidemiology has made available precise and
strict methodologies for the study of diseases.
Pharmacology is the study of the effects of drugs.
Clinical Pharmacology is the study of the effects of drugs in humans, It is traditionally
divided into two basic areas namely:
1. Pharmacokinetics
2. Pharmacodynamics.
Pharmacokinetics is the study of the relationship between dose administered of a drug
and the serum or blood level achieved, it deals with absorption, distribution, metabolism
and excretion.
Epidemiology is the study of the distribution and determinants of diseases in
populations.
Epidemics is the study of chronic/ infectious diseases in large populations.
Pharmacoepidemiology is the study of the use of and the effects of drugs in large
number of people.
It involves the examination of a single individual or large groups of people followed for
many years.
It involves gathering & analysis of information in order to identify possible causation &
related factors, that can be applied in clinical practice to group of people & also to
individuals undergoing treatment.
Pharmacological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Pharmacological approach. Contact me through comment section if you need any assistance in understating
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Dinesh Gangoda
Contents
Guidelines for Preparation of Documentation
Clinical Study Reports
Clinical Trial Monitoring
Safety Monitoring in clinical trials
Introduction
Proper documentation is critical to the success of a clinical study.
Every aspect of the study must be documented in order to obtain useful data and demonstrate compliance with Good Clinical Practice (GCP) guidelines and with all applicable regulations.
Investigator’s Brochure (IB)
List of Abbreviations
Contents & Summary
Introduction provides the chemical name (and generic and trade names, if approved) of the investigational product.
Physical, chemical and pharmaceutical properties and formulation of the medicinal product. Non-clinical studies & Clinical Studies and their results.
The Investigator's Brochure should be reviewed at least annually and revised as necessary in compliance with a standard procedures established by drug development company.
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
Spontenous adr reporting in india
PASSIVE survillence system, data assement
data aciqsition, data interpretation, what all information required in ADR form, WHEN TO REPORT
BLUE CARD,YELLOW CARD, WHO CODES
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
Epidemiology is the study of occurrence, distribution and determinants of health and
diseases or disorders in man and its application in controlling health problems.
Epidemiology has by tradition two major areas.
First is the study of infectious diseases that spread to large populations, i.e., epidemics.
The second is the study of chronic diseases.
Epidemiological studies help to solve such health problems and provide a basis for
improving living conditions of the people.
During its progress and development, epidemiology has made available precise and
strict methodologies for the study of diseases.
Pharmacology is the study of the effects of drugs.
Clinical Pharmacology is the study of the effects of drugs in humans, It is traditionally
divided into two basic areas namely:
1. Pharmacokinetics
2. Pharmacodynamics.
Pharmacokinetics is the study of the relationship between dose administered of a drug
and the serum or blood level achieved, it deals with absorption, distribution, metabolism
and excretion.
Epidemiology is the study of the distribution and determinants of diseases in
populations.
Epidemics is the study of chronic/ infectious diseases in large populations.
Pharmacoepidemiology is the study of the use of and the effects of drugs in large
number of people.
It involves the examination of a single individual or large groups of people followed for
many years.
It involves gathering & analysis of information in order to identify possible causation &
related factors, that can be applied in clinical practice to group of people & also to
individuals undergoing treatment.
The pharma aspirants can read the important information provided in this presentation about Pharmacovigilance which is necessary to qualify the interviews of the same field
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
2. CONTENTS:
› Definition
› why do we need pharmacoepidemiology (PE)
› Origin and Evolution of PE
› Aims of PE
› Methods to perform PE studies.
› Application fields of PE
› Summary
3. Definition:
› Pharmacoepidemiology (PE) is the
study of use and effect of drugs in
large number of population.
› PE is the application of principles
of epidemiology to drug effects
and drug use.
› The term pharmacoepidemiology
contains two components
“Pharmaco” and “epidemiology”
› Pharmaco means drug and
epidemiology means study of
distribution and determinants of
disease in a population.
4. › Epidemiology has two major areas- one is the study of infectious disease in
large population called epidemics and the second is the study of chronic
disease.
› PE involves gathering & analysis of information in order to identify possible
causation & related factors that can be applied in clinical practice to group
of people &also individual undergoing treatment.
› So it examines the relationship b/w drug exposure & health outcome in a
defined population.
5. Why do we need pharmacoepidemiology?
› Information which enhance or supplements the information from
preclinical studies.
1.Better estimation of the incidence or the occurrence of the known adverse
and beneficial effects.
a) Higher precision (e.g. Prazosin)
b) In patients not studied prior to marketing, e.g. the elderly, children,
pregnant women
c) As modified by other drugs and other illnesses (e.g. Timolol)
d) Relative to other drugs used for the same indication
› New types of information not available from premarketing studies.
1. Discovery of previously undetected adverse and beneficial effects like
uncommon effects and delayed effects.
2. Patterns of drug utilization.
3. The economic implications of drug use.
6. Origin and Evolution of PE:
› In 1906 US govt passed pure food and drug act in response to excessive
adulteration & misbranding of food and drugs.
› In 1937 ,over 100 of people died from renal failure as a result of the elixir
sulfanilamide dissolved in diethylene glycol.
› In 1938 D&C act was passed ,because of this manufactures required an approval
from FDA before marketing a drug.
› In 1950 chloramphenicol induced aplastic anaemia was discovered.
› In 1961 , the case reports of maternal use of thalidomide with malformation in
offspring results in awareness of the potential for drugs to cause ADR.
› In 1968 UK established a committee on safety of medicine.
› WHO established a bureau to collect and analyze information from this and similar
national drug monitoring organizations.
› In early 1960, the related field of drug utilization was developed along with the
study of ADRs
› With all these development 1960’s considered to be the beginning of field
of pharmacoepidemiology.
7. › ‘Pharmacoepidemiology’ first appeared in medical literature (BMJ) in 1984.
› ISPE was formed to obtain more data on risk & benefits of drugs in
population and to discuss, develop & disseminateinformation about
pharmacoepidemiologic methods.
DRUG TOXICITY examples:
› Thalidomide
› Chloramphenicol and Grey Baby Syndrome
› Gynecological cancer in offspring of women receiving Diethyl Stilboestrol
› Oculomucocutaneous syndrome with practolol
› Liver disease from Benoxaprofen
› Valvular heart disease from Dexfenfluramine
› Cardiac arrhythmias with terfenadine
› Multiple drug interactions with mibefradil
8.
9. Aim of PE:
› The pharmacoepidemiologic studies concentrate on the period after the
drug enters the market known as post marketing surveillance (PMS)
› These studies are concerned with two main aspects:
1. the study of adverse effects of drugs
2. the appropriate use of medicines
3. Reassurances about drug safety
4. Fulfillment of ethical and legal obligations.
10. Methods to Perform PE studies:
› Ecological/ cross sectional studies
› Case control studies
› Cohort study
› Surveillance systems: Pharmacovigilance
– voluntary reporting
– prescription event monitoring
– medical record linkage
– population statistics
11. Ecological/ Cross sectional studies:
› The results of this type of study design can be compared with other areas
to investigate if there is a difference in the rate of daily purchases of drugs,
which further inform area public health officials of the geography of the
outbreak. Studies using aggregated data are called ecological studies.
› Example:
1. Data on cough and cold preparations bought over-the-counter (OTC) in a
town’s two pharmacies.
2. Total number of packages sold by the pharmacies each day is recorded, but
no data are collected on the individual purchases by patients/customers.
3. Analysis of aggregated data of daily purchases can inform decision-makers on
what types of products are sold or required and may inform public health if
there is a possible outbreak of upper respiratory infection in the area.
4. The data do not necessarily relate it to a particular outcome of interest but
can provide information on the use of medications in a particular population.
12. Limitations:
Confounding arises because there is a lack of individual patient information
Here let us take the confounding factor as smoking, the individual though has cough but the
confounding factor elevates risk of the respiratory depression or illness, in the cross sectional
data the confounding factors are not studied or analysed as we lack individual patient
information.
› Here we measure the aggregate data, This is a simple calculation of the number of people
that are affected by the total population that are at risk. For example, using the above
situation, there were 130 purchases of OTC cough and cold products in 1 day from both
pharmacies. The town has a total population of 5145 people. Therefore, the rate of OTC
cough and cold purchases is 130/5145= 0.025 or 25 purchases per 1000 people
13. Cohort study:
1. Patients receiving a drug are followed up to determine the outcomes
(therapeutic or adverse).
2. This is usually forward-looking (prospective) research. A cohort study
does not require a suspicion of causality; subjects can be followed ‘to see
what happens’(event recording).
3. Prescription event monitoring is an example, and there is an increasing
tendency to recognize that most new drugs should be monitored in this
way when prescribing becomes general.
4. This may take a long time, so cohort studies may take years or generations
until an outcome is identified.
For example, the WHO MONICA Project is a large cohort of 10 million people aged
35-64 from 26 countries of Europe, North America, and Western Pacific. Subjects
were followed forward in time to a fatal or nonfatal cardiovascular event or stroke.
Physical examinations and surveys were performed at regular intervals under a
standardized protocol. This study has provided information on risk factors
contributing to MI and medications used to control blood pressure and their effects
on the mortality rate of acute MI.
14. › A major advantage of cohort studies is that the entire population is at risk
because the study population started the study outcome free. Therefore, an
accurate incidence of the outcome can be calculated for the exposed (Ie) and
unexposed (Io) populations. The incidence is used in the measure of
association termed the relative risk (RR), that is association between a risk
factor and future outcome.
› Incidence of disease is defined as the number of newly diagnosed cases of the disease in a
population divided by the total population at risk of the disease.
15.
16. Case Control study:
1. This reverses the direction of scientific logic from a forward-looking, ‘what
happens next’ (prospective) to a backward-looking, ‘what has happened in
the past’ (retrospective) investigation.
2. The case–control study requires a definite hypothesis or suspicion of
causality, such as an adverse reaction to a drug, The investigator
assembles a group of patients who have the condition.
3. A control group of people who have not had the reaction is then
assembled (matched, e.g. for sex, age, smoking habits) from hospital
admissions for other reasons, primary care records or electoral rolls.
4. A complete drug history is taken from each group, i.e. the two groups are
‘followed up’ backwards to determine the proportion in each group that
has taken the suspect agent.
5. Case–control studies do not prove causation(relationship between
cause and effect) They reveal associations or connection and it is up
to investigators and critical readers to decide the most reasonable
explanation
17. Advantages:
Requires a much smaller number of cases (hundreds) of disease and can thus
be done quickly and cheaply.
Disadvantage:
It follows up subjects backwards and there is always suspicion of the intrusion or interruption
of unknown and so unavoidable biases in the selection of both patients and controls.
› Independent repetition of the studies are performed if the results are the same, greatly
enhances confidence in the outcome.
18. The measure of association for a case control study is the OR. The calculation of the OR is
relatively easy if some simple rules are established and the researcher sets up their results
appropriately to identify the exposure and outcome.
Interpreting the OR can be remembered by using the result to answer cell “A.” For example,
there is an increased/decreased risk of the outcome if exposed to the medication.
19. SURVEILLANCE SYSTEMS: PHARMACOVIGILANCE
› When a drug reaches the market, a good deal is known about its therapeutic
activity but rather less about its safety when used in large numbers of patients with
a variety of diseases, for which they are taking other drugs.
› The term pharmacovigilance refers to the process of identifying and responding to
issues of drug safety through the detection in the community of drug effects,
usually adverse.
› For understandable reasons, they are strongly supported by governments.
Voluntary reporting:
Doctors, nurses, pharmacists and patients may report suspected adverse reaction to
drugs. In the UK, this is called the ‘Yellow Card’ system.
It is recommended that for:
• Newer drugs: all suspected reactions should be reported, i.e. any adverse or
any unexpected event, however minor, that could conceivably be attributed
to the drug
• Established drugs: all serious suspected reactions should be reported, even
if the effect is well recognized.
20. › Voluntary reporting is effective for identifying reactions that develop shortly after
starting therapy, i.e. at providing early warnings of drug toxicity, particularly rare
adverse reactions. Thus, it is the first line in post-marketing surveillance.
› Reporting is low for reactions with long latency, such as tardive dyskinesia from
chronic neuroleptic use.
› As the system has no limit of quantitative or measuring sensitivity, it may detect the
rarest events, e.g. those with an incidence of 1:5000 to 1:10 000.
Prescription event monitoring:
› This is a form of observational cohort study. Prescriptions for a drug (say, 20 000) are
collected (in the UK this is made practicable by the existence of a National Health
Service in which prescriptions are sent to a single central authority for pricing and
payment of the pharmacist).
› The prescriber is sent a questionnaire and asked to report all events that have
occurred (not only suspected adverse reactions) with no judgement regarding
causality. Thus ‘a broken leg is an event. If more fractures were associated with this
drug they could have been due to hypotension, CNS effects or metabolic disease’. By
linking general practice and hospital records and death certificates, both prospective
and retrospective studies can be done and unsuspected effects detected.
21. › Prescription event monitoring can be used routinely on newly licensed
drugs, especially those likely to be widely prescribed in general practice, and
it can also be implemented quickly in response to a suspicion raised, e.g. by
spontaneous reports.
22. Medical record linkage
allows computer correlation in a population of life and health events (birth,
marriage, death, hospital admission) with history of drug use. It is being
developed as far as resources permit. It includes prescription event monitoring
(above). The largest UK medical record linkage is the General Practice
Research Database (GPRD) at the Medicines and Healthcare products
Regulatory Agency.
Population statistics
e.g. birth defect registers and cancer registers. These are insensitive unless a
drug-induced event is highly remarkable or very frequent. If suspicions are
aroused then case–control and observational cohort studies will be initiated.
25. Summary
› The challenge is to identify patterns of use of medical drugs that
compromise their beneficial effects on public health.
› The prerequisite for a medical drug to be marketed is that the information
obtained from clinical trials, i.e. in experimental conditions of use, allows
considering that the benefit it will provide to public health outweighs the
burden of its unavoidable adverse effects.
› Once a medical drug gets marketed, it is no longer used in this experimental,
controlled, setting but in real-life “natural” conditions, in which some
specific patterns of uses or some uses in specific populations can convey
increased risks for public health.
› These uses and associated risks can alter drastically the benefit-risk balance
of the drug and its impact on population health.
26. › The objective of the team is to identify such situations; the key aspects
of the researches conducted in this purpose are the following:
– the more a drug is used, the most important its impact on public health (positive or
negative)
– this impact, in terms of risk, can be increased when the populations
using the drug present with specific frailties, as in the case of cancer
for instance in situations of massive use, even mild to moderate
effects on health induced by drugs can convey a tremendous impact
on public health.
– such mild to moderate changes (beneficial or detrimental) are the
most difficult to identify and quantify in an real-life setting.
– Conducting such researches consequently implies, aside to the
performing of studies applied to specific fields of health, to
continuously develop and assess new methods for the study of drugs
in real-life setting.